Collegium Pharmaceutical, Inc. (COLL) fair value analysis

Nasdaq · Updated 2026-09-07

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes pain management and addiction treatment medications. The company operates primarily in the United States healthcare market.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, COLL is trading at a 10–25% discount to estimated fair value.

COLL currently ranks #44 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $35.58
Sector: Healthcare
12-month range: $31.78–$47.11

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C-
Leverage: High
RSI zone: Oversold
50/200-day trend: Mixed
52-week position: The bottom quarter of its range

What our data shows for COLL

Our model validated 12 trailing price-to-earnings windows for COLL, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $31.78–$47.11.
The 14-day relative strength index sits at an oversold 20.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for COLL
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent COLL news

TickrTrends' derived news-sentiment signal for COLL is currently leaning positive, computed from recent coverage.

A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39 (gurufocus.com, 2026-08-28)
TickrTrends take: Collegium Pharmaceutical trades significantly below its GF Value estimate, which aligns with TickrTrends' assessment that the stock is undervalued within the Healthcare sector. The gap between the valuation estimate and current price suggests the market may be pricing in concerns that a fundamental analysis does not fully support. Investors focused on valuation should monitor whether the company's operational performance and pipeline developments can justify closing this valuation gap over time.
Collegium Announces $50 Million Accelerated Share Repurchase Program (manilatimes.net, 2026-08-13)
TickrTrends take: Collegium's announcement of a $50 million accelerated share repurchase program represents a use of capital that can support per-share metrics, which aligns with TickrTrends' current undervalued assessment of the Healthcare sector company. Share repurchases reduce the outstanding share count, a factor that can influence earnings per share calculations and other per-share valuation ratios that investors monitor. For valuation-focused readers tracking COLL, the execution and timing of this buyback program may provide relevant context for understanding changes in per-share financial measures in upcoming reporting periods.
Collegium Pharmaceutical, Inc. Q2 2026 Earnings Call Summary (finance.yahoo.com, 2026-08-07)
TickrTrends take: Collegium Pharmaceutical's Q2 2026 earnings call provides an opportunity to assess whether the company's operational performance and financial trajectory support TickrTrends' current undervalued designation. A valuation-focused reader should monitor management commentary on revenue trends, margin expansion, and cash flow generation to determine if the company's fundamentals justify tighter valuation multiples relative to its Healthcare sector peers. The earnings discussion will be particularly relevant for evaluating whether the undervalued assessment reflects sustainable competitive positioning or near-term market mispricing in a sector subject to regulatory and competitive pressures.

What people are saying

Follow the COLL conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is COLL stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), COLL is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is COLL's TickrTrends verdict?

COLL's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does COLL compare to other Healthcare stocks?

COLL ranks #44 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is COLL overbought or oversold?

COLL's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.

All Healthcare fair-value coverage →

Head-to-head comparisons

COLL vs ABT · COLL vs BTSG · COLL vs DVA · COLL vs EXEL · COLL vs GMAB